Yachuang Medicine

Based in China, Yachuang Medicine specializes in developing innovative therapies for chronic liver diseases, particularly focusing on Non-alcoholic Steatohepatitis (NASH) and Chronic Hepatitis B Infection (HBV). Yachuang Medicine, founded in 2016, is headquartered in Shanghai, China. The company focuses on developing treatments for chronic liver diseases. It has completed 2 funding deals, raising USD 40.

00 mn in its most recent Series B funding round in April 2021, led by Loyal Valley Capital, and including investors such as Apricot Capital and Oceanpine Capital. Yachuang Medicine, through its subsidiary Hepagene Therapeutics, Inc. , is committed to developing innovative therapies targeting chronic liver diseases like Non-alcoholic Steatohepatitis (NASH) and Chronic Hepatitis B Infection (HBV). Their lead drug candidate, HPG1860, is currently undergoing Phase I clinical trials to meet the needs of patients affected by NASH, which is characterized by liver inflammation and fat accumulation.

The company also targets various patient groups, including those with obesity, diabetes, and metabolic syndrome, and has a pipeline for other HBV compounds, operating in significant markets in North America and Europe. Yachuang Medicine generates revenue primarily through the advancement and commercialization of its therapeutic candidates, focusing on partnerships with pharmaceutical companies and research institutions. The revenue structure involves licensing agreements, milestone payments upon achieving clinical endpoints, and royalties from future sales of marketed products. HPG1860 is expected to follow this model, positioning the company to build long-term relationships within the healthcare ecosystem.

Following its Series B funding round of USD 40. 00 mn in April 2021, Yachuang Medicine aims to expand its product offerings and geographic reach. The funding will support the continued development of HPG1860 and potentially new candidates targeting liver diseases. The company plans to enhance its presence in North America and Europe, with strategic partnerships to accelerate market entry and product commercialization.